Accedi a banche dati online | Convegnodetail
mail
Anteprima di stampa
 
 

ALS Drug Development Summit

Evvnt Promotion / evvnt
-
24.05.2022 - 26.05.2022  Hyatt Regency Boston, 1 Avenue de Lafayette, 02111 Boston, USA
Time: 09:00 - 16:30
 
Temi della conferenza
Meaningful progress in establishing causative genetic mutations and environmental factors implicated in ALS disease progression and advances in validating emerging biomarkers to evaluate treatment response has meant that the landscape for drug development in ALS is exploding. With exciting new targets, revised inclusion criteria, and opportunities to implement digital biomarkers for remote and sensitive monitoring, we have never been closer to bringing meaningful therapies to patients.
Professional congress organizer (PCO)
Hanson Wade
Annotazioni
Speakers: Amir Lahav, Head of Digital R and D, Digital Healthcare Innovation, Mitsubishi Tanabe Pharma Holdings America, Andrew Wolff, Senior Vice President, Senior Fellow, Clinical Research and Development, Cytokinetics and more.
 

Informazioni ed Iscrizioni:

https://go.evvnt.com/1004834-2?pid=4832
Ms. Stephanie Nketia
 
Categorie
Medicina General
Lingua
Inglese
Quote del Congresso
USD 2199.0 - USD 4297.0
Contatto organizzatori
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Noi, Going International, siamo un’azienda che si è scelta come obiettivo di rendere acessibile la formazione a una grandissima quantità di persone, oltrepassanddo i confini geografici e sociali."

Ärzte der WeltSwiss Tropical and Public Health InstituteCenter of ExcellenceÖsterreichische Gesellschaft für Public HealthCharité International AcademyOÖ Gebietskrankenkasse, Referat für Wissenschaftskooperation newTreeHelix - Forschung & Beratung Wien